Durvalumab as maintenance therapy for limited-stage small cell lung cancer
Part of Cancer clinical trials.
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have limited-stage small cell lung cancer (Stage I to III) that cannot be removed by surgery (if Stage I or II).
- You received chemotherapy and radiation as your first treatment, and the cancer did not get worse during that time.
- You started taking Durvalumab (Imfinzi) within 3 months after finishing radiation, and have taken at least one dose.
- You do not have an active autoimmune disease (like lupus or rheumatoid arthritis) or other serious health problems that are not under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
This trial tests a new combination of drugs (atigotatug and nivolumab) against the standard drug durvalumab for people with limited-stage small cell lung cancer who have completed chemotherapy and radiation without the cancer getting worse. The goal is to see if the new combination works better at keeping the cancer from coming back.
Hear when a new SCLC, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.